Apimeds Pharmaceuticals US, Inc. (APUS) Fair Value 2026

APUS · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.0 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (13/100)

Quick Summary — As of 2026-08-28, Apimeds Pharmaceuticals US, Inc. (APUS) trades at $3.87. QOC: 5.0/10. Value Trap Risk: 13/100 (SAFE). 1/13 models active.

Key Facts

Ticker
APUS
Price
$3.87
Quality Score
5.0/10
Value Trap Risk
13/100
Models Active
1/13
Last Updated
Strength: ML-RIV suggests +53.0% upside with 44% confidence
Risk: Below-average Quality Score of 5.0/10 signals weak fundamentals

What Fair Value Does Each Model Give APUS?

1 Intrinsic Value Models vs. Current Price ($3.87)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $5.92 +53.0%

All Models Active

All 1 models are displayed above.

What Is Apimeds Pharmaceuticals US, Inc. (APUS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Apimeds Pharmaceuticals US, Inc.'s intrinsic value is estimated at a median fair value of $5.92. At a current market price of $3.87, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +53.0%.

What Do the Models Say About APUS?

1 of 13 models are currently active for APUS. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does APUS Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, APUS ranks #80 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Within the Drug Manufacturers - Specialty & Generic space, Apimeds Pharmaceuticals US, Inc. competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is APUS a Value Trap?

CirclFi's Value Trap algorithm assigns APUS a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Apimeds Pharmaceuticals US, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Apimeds Pharmaceuticals US, Inc. is rated at 5.0/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every APUS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across APUS's 1 active models, average confidence is 44%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Apimeds Pharmaceuticals US, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

CANNTrees CorporationQOC 5.1HYEXHealthy Extracts Inc.QOC 4.9IXHLIncannex Healthcare Inc.QOC 5.1RGCRegencell Bioscience Holdings LimitedQOC 4.8NTRRNeutra Corp.QOC 5.1OWPCOne World Products, Inc.QOC 4.7KMDAKamada Ltd.QOC 2.6TRLVTrulieve Cannabis Corp.QOC 7.3INCRInterCure Ltd.QOC 6.1UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: CANN · HYEX · IXHL · RGC · NTRR · OWPC · KMDA · TRLV · INCR · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to APUS?

7 companies across all industries closest to APUS’s Quality of Company score of 5.0/10.

LUNRIntuitive Machines, Inc.QOC 5.0CNICanadian National Railway CompanyQOC 5.0DTCXDatacentrex, Inc.QOC 5.0CETYClean Energy Technologies, Inc.QOC 5.0ALLOAllogene Therapeutics, Inc.QOC 5.0NEWHNewHydrogen, Inc.QOC 5.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LUNR · CNI · DTCX · CETY · ALLO · NEWH · NVDA

Where Does APUS Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

APUS is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Apimeds Pharmaceuticals US, Inc.’s Valuation?

What is Apimeds Pharmaceuticals US, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Apimeds Pharmaceuticals US, Inc. (APUS). The Quality of Company score is 5.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is APUS overvalued or undervalued right now?

At $3.87, 1 of 1 active models suggest APUS may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Apimeds Pharmaceuticals US, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.0 mean for APUS?

Apimeds Pharmaceuticals US, Inc.'s QOC of 5.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on APUS?

CirclFi analyzes APUS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is APUS a value trap in 2026?

Apimeds Pharmaceuticals US, Inc.'s Value Trap score is 13/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Apimeds Pharmaceuticals US, Inc. (APUS) a Quality of Company score of 5.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/APUS/ · Methodology
Primary sources for this APUS valuation
  • Financial statements: Apimeds Pharmaceuticals US, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001894525) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for APUS as of ; valuations recomputed .